LaseMD System for the Treatment of Melasma
Evaluation of the Lutronic LaseMD System for the Treatment of Melasma
Sponsor: CynosureLutronic
Listed as NCT03456674, this NA trial focuses on Melasma and remains ongoing. Sponsored by CynosureLutronic, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting NA
-
Sep 2024 — Feb 2026 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Aug 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
Status: Unknown Status → Active Not Recruiting
-
Oct 2021 — Aug 2023 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
▶ Show 5 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Apr 2019 [monthly]
Recruiting NA
-
Mar 2018 — Jun 2018 [monthly]
Recruiting NA
First recorded
Feb 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CynosureLutronic
For direct contact, visit the study record on ClinicalTrials.gov .